Abstract
Overview
Introduction
Datamonitor expects the continuously growing prevalence of diabetes to drive
growth in diabetes drug spending, benefiting market uptake of newly developed,
efficacious therapies. A variety of novel, non-insulin antidiabetic agents are
poised to become available to patients in the next decade, with two DPP-4
inhibitors likely to launch in 2007 and two GLP-1 agonists entering the market
by 2010.
Scope
- Assessment of the patient potential for developmental non-insulin agents
in the type 2 diabetes setting of over the period 2006-15
- Overview of the non-insulin antidiabetics R&D pipeline, with detailed
information on the classes in development and comparator drugs
- Commercial analysis of key compounds in development regarding their
ability to satisfy key unmet needs, supported by the views of key opinion
leaders
- Sales forecasts for key late-stage developmental non-insulin antidiabetics
in the seven major markets to 2015
Highlights
The diabetes market is worthy of investment because of the endemic size of its
patient pool which is set to grow further, and the nature of its unmet
clinical needs. This situation is reflected in the R&D pipeline for
non-insulin antidiabetics, comprising a diverse collection of 76 novel agents
in clinical development.
Datamonitor has identified five late-stage candidate drugs likely to be
launched in the diabetes market within the next five years. These are the
DPP-4 inhibitors Galvus and Januvia, the GLP-1 agonists Byetta LAR and
liraglutide, the PPAR-gamma modulator metaglidasen. Apart from metaglidasen,
all four agents have blockbuster potential.
Despite the fact that pipeline products will impact the diabetes market
greatly in the next five years, there are currently no agents in late-stage
clinical development that are likely to fully replace current mainstays of
antidiabetic therapy. Type 2 diabetes is therefore likely to remain an add-on
market rather than develop into a switch market.
Reasons to Purchase
- Understand the key factors that will contribute to the success of the next
generation of anti-diabetes drugs
- View independent sales forecasts for products in late stage development
for therapy of type 2 diabetes
- Understand physician sentiment on clinical trial endpoints and late-stage
candidate drugs for the diabetes market
| 
View Cart
